0000000000218350

AUTHOR

Emile E. Voest

showing 5 related works from this author

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Cl…

2017

AbstractPurpose: This study investigated the safety, clinical activity, and target-associated biomarkers of lumretuzumab, a humanized, glycoengineered, anti-HER3 monoclonal antibody (mAb), in combination with the EGFR-blocking agents erlotinib or cetuximab in patients with advanced HER3-positive carcinomas.Experimental Design: The study included two parts: dose escalation and dose extension phases with lumretuzumab in combination with either cetuximab or erlotinib, respectively. In both parts, patients received lumretuzumab doses from 400 to 2,000 mg plus cetuximab or erlotinib according to standard posology, respectively. The effect of HRG mRNA and HER3 mRNA and protein expression were inv…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtyReceptor ErbB-3Neuregulin-1CetuximabPharmacologyAntibodies Monoclonal Humanized03 medical and health sciencesErlotinib Hydrochloride0302 clinical medicineInternal medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorMedicineHumansAdverse effectneoplasmsSurvival analysisCetuximabbusiness.industryCancerLumretuzumabmedicine.diseaseSurvival Analysisrespiratory tract diseasesClinical trialGene Expression Regulation Neoplastic030104 developmental biologyTreatment OutcomeOncology030220 oncology & carcinogenesisMonoclonalFemaleErlotinibbusinessmedicine.drugClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)

2016

The European Society for Medical Oncology (ESMO) is one of the leading societies of oncology professionals in the world. Approximately 30% of the 13 000 ESMO members are below the age of 40 and thus meet the society's definition of young oncologists (YOs). ESMO has identified the training and development of YOs as a priority and has therefore established a comprehensive career development programme. This includes a leadership development programme to help identify and develop the future leaders in oncology. Well-trained and highly motivated future generations of multidisciplinary oncologists are essential to ensure the optimal evolution of the field of oncology with the ultimate goal of pro…

Oncologymedicine.medical_specialtyCancer ResearchReviewFellowshipExecutive boardMultidisciplinary approachInternal medicineJournal ArticleMedicine15061507Leadership developmentbusiness.industryLeadership ProgrammeGénéralitésESMOTraining and developmentYoung OncologistsOncologyESMO; Fellowship; Leadership Programme; Preceptorship; Young OncologistsPreceptorshipPortfoliobusinessCareer developmentESMO; Fellowship; Leadership Programme; Preceptorship; Young Oncologists; Cancer Research; Oncology
researchProduct

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3…

2016

Abstract Purpose: A first-in-human phase I study was conducted to characterize safety, efficacy, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of lumretuzumab, a humanized and glycoengineered anti-HER3 monoclonal antibody, in patients with advanced cancer. Experimental Design: Twenty-five patients with histologically confirmed HER3-expressing tumors received lumretuzumab (100, 200, 400, 800, 1,600, and 2,000 mg) every two weeks (q2w) in 3+3 dose-escalation phase. In addition, 22 patients were enrolled into an extension cohort at 2,000 mg q2w. Results: There were no dose-limiting toxicities. Common adverse events (any grade) included diarrhea (22 patients, 46.8%), fatigue (21 …

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyPathologyMaximum Tolerated DoseReceptor ErbB-3CmaxAntibodies Monoclonal HumanizedResearch SupportGastroenterologyClinical Trial Phase I03 medical and health sciencesPhase I0302 clinical medicinePharmacokineticsInternal medicineJournal ArticlemedicineHumansNon-U.S. Gov'tAdverse effectAgedAnalgesicsbusiness.industryResearch Support Non-U.S. Gov'tCancerMiddle AgedLumretuzumabmedicine.diseaseClinical TrialMulticenter StudyTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisPharmacodynamicsMonoclonalFemaleColorectal NeoplasmsbusinessEx vivo
researchProduct

The Porto European Cancer Research Summit 2021.

2021

Key stakeholders from the cancer research continuum met in May 2021 at the European Cancer Research Summit in Porto to discuss priorities and specific action points required for the successful implementation of the European Cancer Mission and Europe's Beating Cancer Plan (EBCP). Speakers presented a unified view about the need to establish high‐quality, networked infrastructures to decrease cancer incidence, increase the cure rate, improve patient's survival and quality of life, and deal with research and care inequalities across the European Union (EU). These infrastructures, featuring Comprehensive Cancer Centres (CCCs) as key components, will integrate care, prevention and research acros…

Cancer Researchmedicine.medical_specialty:Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores]infrastructures for translational cancer researchDeclarationTranslational researchContext (language use)comprehensive cancer centresMeeting Reportclinical/prevention trials:profesiones sanitarias::medicina::medicina clínica::medicina de precisión [DISCIPLINAS Y OCUPACIONES]Translational Research Biomedicaloutcomes research:neoplasias [ENFERMEDADES]:Other subheadings::Other subheadings::/prevention & control [Other subheadings]cancer research/care/prevention continuumNeoplasmsPolitical scienceGeneticsmedicineHumansmedia_common.cataloged_instance:Health Occupations::Medicine::Clinical Medicine::Precision Medicine [DISCIPLINES AND OCCUPATIONS]Medicina personalitzadaPrecision MedicineEuropean unionRC254-282media_commongeographySummitgeography.geographical_feature_categoryHealth economics:Natural Science Disciplines::Science::Research::Biomedical Research [DISCIPLINES AND OCCUPATIONS]Neoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineCancer MissionEuropescience policy:Neoplasms [DISEASES]Medicina - InvestigacióOncologyQuality of LifeCancer researchMolecular MedicineScience policyCàncer - PrevencióOutcomes research:disciplinas de las ciencias naturales::ciencia::investigación::investigación biomédica [DISCIPLINAS Y OCUPACIONES]
researchProduct

A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced/metastatic tumors of epithelial cel…

2013

2522 Background: The Human Epidermal Growth Factor Receptor 3 (HER3) is a key heterodimerization partner for other HER family members thereby acting as a downstream signal amplifier. This is a first in human study evaluating the safety of RG7116, a humanized anti-HER3 monoclonal antibody with potent HER3 signal inhibition. Due to a glycoengineered Fc-part this antibody displays enhanced antibody-dependent cellular cytotoxicity as compared to conventional antibodies. Methods: Patients (pts) with advanced or metastatic carcinomas with centrally confirmed HER3 protein expression were included. A “3+3” dose escalation design was performed starting at 100 mg flat dosing in a q2w regimen. In add…

Cancer Researchmedicine.drug_classbusiness.industryFirst in humanMonoclonal antibodyEpitheliumSignal amplifiermedicine.anatomical_structureOncologyDownstream (manufacturing)Cancer researchmedicineHuman epidermal growth factor receptorIn patientbusinessJournal of Clinical Oncology
researchProduct